Celon Pharma SA (8RP) Stock Statistics & Valuation Metrics

Celon Pharma SA has a market cap or net worth of €237.26M. The enterprise value is €1.07K.

Celon Pharma SA has 53,911,500 shares outstanding. The number of shares has decreased by -2.65% in one year.

Celon Pharma SA’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -14.09%.

The current PE Ratio of Celon Pharma SA is 8.9. Celon Pharma SA’s PEG ratio is -0.11.

In the last 12 months, Celon Pharma SA had revenue of 209.80M and earned -79.36M in profits. Earnings per share was -1.47.

In the last 12 months, operating cash flow was 27.29M and capital expenditures -83.92M, giving a free cash flow of -56.63M billion.

Celon Pharma SA pays an annual dividend of ―, resulting in a dividend yield of ―

Celon Pharma SA upcoming earnings date is Nov 18, 2026, TBA (Confirmed).

Celon Pharma SA as a current ratio of 1.62, with Debt / Equity ratio of 25.76%

In the past 12 months, Celon Pharma SA has paid 20.40M in taxes.

Celon Pharma SA EV to EBITDA ratio is -104.55, with an EV/FCF ratio of -35.84.

Celon Pharma SA has €34.53M in cash and marketable securities with €128.44M in debt, giving a net cash position of -€93.91M billion.

Gross margin is 6.76%, with operating margin of -27.06%, and net profit margin of -37.83%.

The average price target for Celon Pharma SA is ―, which is 11.43% higher than the current price. The consensus rating is ―